CYBA and autosomal dominant polycystic kidney disease: As shown in Figure 1, p22phox protein expression was significantly higher in untreated ADPKD patients compared to that in both tolvaptan-treated ADPKD patients and healthy subjects: 1.42 ± 0.11 vs. 0.86 ± 0.15, p = 0.015, vs. 0.53 ± 0.11 densitometric units, p < 0.001, respectively.